about
Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR ImagesAntivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRIVascular endothelial growth factor as an anti-angiogenic target for cancer therapyPreclinical molecular imaging of tumor angiogenesis.Inter- and intra-rater reproducibility of quantitative dynamic contrast enhanced MRI using TWIST perfusion data in a uterine fibroid model.Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.Phage display peptide probes for imaging early response to bevacizumab treatment.Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.Unsupervised deconvolution of dynamic imaging reveals intratumor vascular heterogeneity and repopulation dynamics.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancerA perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentPET imaging of early response to the tyrosine kinase inhibitor ZD4190.High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcomeMRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft modelImaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.Anti-VEGF therapy: the search for clinical biomarkers.HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluationPET Imaging of Angiogenesis.DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.MRI & MRS assessment of the role of the tumour microenvironment in response to therapy.Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model.Assessment of Treatment Response With Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI in Patients With Early-Stage Breast Cancer Treated With Single-Dose Preoperative Radiotherapy: Initial Results.Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.The role of endorectal magnetic resonance imaging in predicting extraprostatic extension and seminal vesicle invasion in clinically localized prostate cancerDynamic contrast-enhanced MR evaluation of prostate cancer before and after endorectal high-intensity focused ultrasound.Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging.The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy.Dynamic contrast enhanced-MRI in head and neck cancer patients: variability of the precontrast longitudinal relaxation time (T10)Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinomaRegional heterogeneity changes in DCE-MRI as response to isolated limb perfusion in experimental soft-tissue sarcomas
P2860
Q26743358-9194951F-C0A1-4C27-987A-6F60F8C73D63Q28268126-2259222D-EDD7-461B-AACA-80593E9F0272Q30455612-6AA1CE53-2B1D-4DD8-B73C-EC686492B9BCQ30475818-C9E1C1E8-2778-4DC8-ABDD-11C964E14B2FQ30581552-80B2F806-A7B8-4A85-AF79-FA688C1B6C00Q33217481-5C16F2C0-9E04-4D44-9741-C303BAF87463Q33541076-531BF28E-D6AE-40D1-AE72-93A30EE2816DQ34145257-1E8BF67C-24AB-4C17-A29A-B36DCB9FEC77Q34367593-B1289B7D-462A-4B37-AC8B-37313E0A08A2Q34391672-404084ED-A3C9-4945-8580-752CDFA20D5FQ34473011-9D33055F-8ED3-434E-B590-EDB79194F8EFQ34538659-5A542FF3-286C-4908-88DC-14E822ACBF07Q34765364-C4931335-F883-424E-BA90-E728AC4E3441Q35249646-4F7A9413-0351-41EB-B701-6E90C2B05846Q35625666-09F92D03-6BC1-4903-89DE-C85C71808F33Q35668680-25E2E7E3-09D3-46D6-844A-1891024F5316Q35880395-1F8D0724-1EDC-484F-A0DA-C1DB3CDB3F61Q36567385-5F55260F-7F1B-423A-A26C-9169FD1AF8BBQ36972860-0BE2E34C-A377-4507-BDF8-171A6E1D3830Q37206167-DA5C9E29-F482-49D0-B706-A769BACF2A0EQ37246034-B1D73BC7-0C37-45C2-A557-37D489286FC4Q37366243-8E57510C-8AEA-459A-B0CD-2A91A191085BQ37418739-B4FF8EEC-61F2-43E4-A9B9-9BFCCF46295BQ37875004-CB76EC17-4DD0-42D5-B96A-7F1BBF8D7C0DQ38925774-1070A227-2E84-435C-B0EB-4D0DC9F0A0DBQ38989194-8E57A328-8990-432A-A9D1-02C16B16597FQ40127766-3C4380B0-32A9-4CDF-A89B-B793FC698E87Q40666457-2B50D59C-A75C-47FF-A65D-119B901640A2Q50244867-D5D003AB-8E52-421D-92D6-96483BE7E99DQ51240087-CCDBB877-B362-469B-A414-1450D2A8D699Q51808119-7752A325-73DB-448E-AA9D-843574BD5072Q53099218-0193EC3F-DB87-4E90-B770-F5CFEFB3682AQ57154307-35AA6104-9986-4571-992A-79445CD2ECA0Q57317511-B50A6D59-A480-41FF-A179-1CA08FFEEE63Q57719785-7D3C04CE-C135-4849-B18B-291C7BB6EE91
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
MRI for assessing antivascular cancer treatments.
@ast
MRI for assessing antivascular cancer treatments.
@en
type
label
MRI for assessing antivascular cancer treatments.
@ast
MRI for assessing antivascular cancer treatments.
@en
prefLabel
MRI for assessing antivascular cancer treatments.
@ast
MRI for assessing antivascular cancer treatments.
@en
P2860
P356
P1476
MRI for assessing antivascular cancer treatments.
@en
P2093
Padhani AR
P2860
P304
P356
10.1259/BJR/15334380
P407
P478
76 Spec No 1
P577
2003-01-01T00:00:00Z